中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2008年
5期
760-761
,共2页
薛海燕%徐峰%冯泽蛟%陈文殊%陈新宵
薛海燕%徐峰%馮澤蛟%陳文殊%陳新宵
설해연%서봉%풍택교%진문수%진신소
腺肌病%环氧化酶2%血管内皮生长因子%子宫
腺肌病%環氧化酶2%血管內皮生長因子%子宮
선기병%배양화매2%혈관내피생장인자%자궁
Adenomyosis%Cyclooxygenase-2%Vascular endothelial growth factor%Uterus
目的 探讨环氧化酶2(COX-2)和血管内皮生长因子(VEGF)在子宫腺肌病中异位内膜及在位内膜中的表达及其临床意义.方法 应用免疫组织化学法检测COX-2和VEGF在子宫在位内膜、异位内膜和正常内膜中的表达差异.结果 (1)COX-2在子宫腺肌病(观察组)异位内膜表达评分(4.62±0.96)、在位内膜中的表达评分(4.59±0.77)与正常子宫内膜组(3.55±1.276)间比较差异有统计学意义(P<0.05);异位内膜与在位内膜中COX-2表达差异无统计学意义(P0.05).(2)VEGF在子宫腺肌病(观察组)异位内膜中的表达评分(4.62±0.96)、在位内膜中的表达评分(4.59±0.77)与正常内膜组(4.30±0.81)比较,差异有统计学意义(P<0.05).(3)COX-2和VEGF在子宫腺肌病患者异位内膜中的表达呈正相关(P<0.05).结论 COX-2和VEGF在子宫腺肌病的发生、发展中起着关键性作用,两者在血管生成过程中密切相关,可能为子宫腺肌病的治疗提供新的靶点.
目的 探討環氧化酶2(COX-2)和血管內皮生長因子(VEGF)在子宮腺肌病中異位內膜及在位內膜中的錶達及其臨床意義.方法 應用免疫組織化學法檢測COX-2和VEGF在子宮在位內膜、異位內膜和正常內膜中的錶達差異.結果 (1)COX-2在子宮腺肌病(觀察組)異位內膜錶達評分(4.62±0.96)、在位內膜中的錶達評分(4.59±0.77)與正常子宮內膜組(3.55±1.276)間比較差異有統計學意義(P<0.05);異位內膜與在位內膜中COX-2錶達差異無統計學意義(P0.05).(2)VEGF在子宮腺肌病(觀察組)異位內膜中的錶達評分(4.62±0.96)、在位內膜中的錶達評分(4.59±0.77)與正常內膜組(4.30±0.81)比較,差異有統計學意義(P<0.05).(3)COX-2和VEGF在子宮腺肌病患者異位內膜中的錶達呈正相關(P<0.05).結論 COX-2和VEGF在子宮腺肌病的髮生、髮展中起著關鍵性作用,兩者在血管生成過程中密切相關,可能為子宮腺肌病的治療提供新的靶點.
목적 탐토배양화매2(COX-2)화혈관내피생장인자(VEGF)재자궁선기병중이위내막급재위내막중적표체급기림상의의.방법 응용면역조직화학법검측COX-2화VEGF재자궁재위내막、이위내막화정상내막중적표체차이.결과 (1)COX-2재자궁선기병(관찰조)이위내막표체평분(4.62±0.96)、재위내막중적표체평분(4.59±0.77)여정상자궁내막조(3.55±1.276)간비교차이유통계학의의(P<0.05);이위내막여재위내막중COX-2표체차이무통계학의의(P0.05).(2)VEGF재자궁선기병(관찰조)이위내막중적표체평분(4.62±0.96)、재위내막중적표체평분(4.59±0.77)여정상내막조(4.30±0.81)비교,차이유통계학의의(P<0.05).(3)COX-2화VEGF재자궁선기병환자이위내막중적표체정정상관(P<0.05).결론 COX-2화VEGF재자궁선기병적발생、발전중기착관건성작용,량자재혈관생성과정중밀절상관,가능위자궁선기병적치료제공신적파점.
Objective To discuss the expression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in adenomyosis and its clinical significance. Methods The expression of COX-2 and VEGF was examined by immunohistochemistry SP method, in ectopic endometrium and eutopic endometrium, compared with normal endometrium. Results (1) COX-2 expression in ectopic, eutopic endometrium with adenomyosis was significantly higher than that in control group (P<0.05). No statistically significant difference was found between ectopic endometrium and eutopic endometrium group with adenomyosis (P0.05).(2) VEGF expressions in ectopic, eutopic endometrium with adenomyosis were both significantly higher than that of control group (P<0.05); no statistically significant difference was found between ectopic endometrium and eutopic endometrium group (P0.05).(3) COX-2 and VEGF had the positive relativity in the ectopic endometriumal expression of adenomyosis patient (P<0.05). Conclusion COX-2 and VEGF may play a key role in adenomyosis. Both may have close relation in angiogenesis and may provide new targets for therapy of adenomyosis.
